- 10 clinical trials to watch in the second half of 2026<p>The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to…BioPharma Dive · 26d ago↗ source
- FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…BioPharma Dive · 29d ago↗ source
- At BIO, tension over China biotech deal regulation looms<figure><div><img src="https://imgproxy.divecdn.com/QMMgdLWmV9_RV75ozi_JOVMqLcnMq3yXkrVCs0nJ7_U/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTgyOTQ2OTI4LmpwZ…